Trial Profile
Safety and Efficacy of Nivolumab and Pembrolizumab Among HIV-Positive Patients with Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications HIV infections; Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Apr 2018 New trial record
- 06 Apr 2018 Results published in the Journal of Thoracic Oncology.